Adriano C.
- Country
- Italy
- Department
- SC Neurologia 1 U
Research Overview
- Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis: A Phase 3, Randomized, Double-blind, Placebo-controlled Study
- Phase 1b/2 Study of Oral NB-4746 with Standard Riluzole in Participants with Amyotrophic Lateral Sclerosis: Safety and Tolerability Assessment
- Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: An Open-label Extension Study
Data & Insights
Has run more than one trial at 46 of 101 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the treatment of rare neuromuscular conditions, with particular focus on Spinal and Bulbar Muscular Atrophy (SBMA) and various forms of Amyotrophic Lateral Sclerosis (ALS).
- Standard ALS
- FUS-mutation ALS
- SOD1-mutation ALS
- SBMA therapeutics
The research activities encompass innovative therapeutic approaches for treating different genetic variants of motor neuron diseases.
Genetic Disease Variants
The investigator conducts research in genetic mutations associated with neurodegenerative conditions, specifically focusing on presymptomatic treatment approaches.
- SOD1 mutation carriers
- FUS mutation variants
- Presymptomatic intervention
The work includes assessment of targeted therapies for specific genetic variants of neurological disorders.
Autoimmune Conditions
Research extends to autoimmune neurological disorders, particularly Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and its treatment modalities.
- CIDP therapeutics
- Subcutaneous treatments
- Long-term disease management
The focus includes investigation of novel treatment delivery methods for autoimmune neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.